Mycobacterium indicus pranii induces dendritic cell activation, survival, and Th1/Th17 polarization potential in a TLR-dependent manner-Reference-Cited by-同舟云学术

Mycobacterium indicus pranii induces dendritic cell activation, survival, and Th1/Th17 polarization potential in a TLR-dependent manner

Published:2015-01-15 Issue:3 Volume:97 Page:511-520
ISSN:0741-5400
Container-title:Journal of Leukocyte Biology
language:en
Short-container-title:Journal of Leukocyte Biology

Author:

Kumar Pawan,John Vini,Marathe Soumitra,Das Gobardhan,Bhaskar Sangeeta

Funder

National Institute of Immunology, New Delhi, India

Publisher

Wiley

Subject

Cell Biology,Immunology,Immunology and Allergy

Reference37 articles.

1. Dendritic cell subsets and the regulation of Th1/Th2 responses;Maldonado-López;Semin. Immunol.,2001

2. Correlation between the kinetics of Th1, Th2 cells and pathology in a murine model of experimental pulmonary tuberculosis;Hernández-Pando;Immunology,1996

3. Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis;Winau;Immunity,2006

4. Mycobacterium tuberculosis inhibition of phagolysosome biogenesis and autophagy as a host defence mechanism;Deretic;Cell. Microbiol.,2006

5. Mycobacteria target DC-SIGN to suppress dendritic cell function;Geijtenbeek;J. Exp. Med.,2003

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synergistic Role of Mycobacterium Indicus Pranii and Human Beta Defensin-2 as Adjunctive Therapy Against Mycobacterium Tuberculosis;2024

2. Type 1 interferon mediated signaling is indispensable for eliciting anti-tumor responses by Mycobacterium indicus pranii;Frontiers in Immunology;2023-04-14

3. Mycobacterium Indicus Pranii (MIP) Vaccine: Pharmacology, Indication, Dosing Schedules, Administration, and Side Effects in Clinical Practice;Indian Dermatology Online Journal;2023

4. Tumor targeted delivery of mycobacterial adjuvant encapsulated chitosan nanoparticles showed potential anti-cancer activity and immune cell activation in tumor microenvironment;International Immunopharmacology;2023-01

5. Microbial-Derived Toll-like Receptor Agonism in Cancer Treatment and Progression;Cancers;2022-06-14